N. Lydon

发表

The structure-based design of ATP-site directed protein kinase inhibitors.

L. Toledo, N. Lydon, D. Elbaum, 1999, Current medicinal chemistry.

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

P. Furet, N. Lydon, P. Traxler, 1997, Journal of medicinal chemistry.

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.

P. Furet, N. Lydon, P. Traxler, 1996, Journal of medicinal chemistry.

Inhibition of epidermal growth factor-mediated ERK1/2 activation by in situ electroporation of nonpermeant [(alkylamino)methyl]acrylophenone derivatives.

T. Roberts, N. Lydon, E. Schaefer, 1998, DNA and cell biology.

Hepatitis B virus polymerase gene: expression of the long open reading frame using the baculovirus expression system.

N. Lydon, H. Will, E. McGlynn, 1992, The Journal of general virology.

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

B. Druker, N. Lydon, E. Buchdunger, 2000, The Journal of pharmacology and experimental therapeutics.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

C. Sawyers, H. Kantarjian, J. Ford, 2001, The New England journal of medicine.

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Jürg Zimmermann, Brian J. Druker, B. Druker, 1996, Nature Medicine.

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

N. Lydon, M. Di Nicola, C. Gambacorti-Passerini, 1997, Blood cells, molecules & diseases.

CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.

M. Carroll, B. Druker, N. Lydon, 1997, Blood.

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

T. Meyer, B. Druker, N. Lydon, 1996, Cancer research.

Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

Jürg Zimmermann, N. Lydon, H. Mett, 1997 .

Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.

N. Lydon, P. Traxler, T. Meyer, 1992, Cancer research.

Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.

N. Lydon, P. Traxler, T. Meyer, 1990, The Journal of biological chemistry.

Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors.

R. Cozens, N. Lydon, H. Mett, 1992, European journal of biochemistry.

Cdc2-mediated modulation of pp60c-src activity.

N. Lydon, J. Liebetanz, D. Stover, 1994, The Journal of biological chemistry.

A potent protein‐tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor‐expressing tumor cells in vitro and in vivo

R. Cozens, N. Lydon, P. Traxler, 1998 .

Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors.

L. Toledo, N. Lydon, 1997, Structure.

A potent protein‐tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor‐expressing tumor cells in vitro and in vivo. Int. J. Cancer, 76, 154–163 (1998)

R. Cozens, N. Lydon, P. Traxler, 1999, International journal of cancer.

A strategy for screening anti‐tumor drugs utilizing oncogenes encoded in retroviral vectors

T. Roberts, N. Lydon, P. Traxler, 1996, International journal of cancer.

Cellular and In Vivo characterization of the MCR rat mammary tumor model

N. Lydon, A. Matter, U. Regenass, 1993, International journal of cancer.

Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

Z. Estrov, H. Kantarjian, N. Lydon, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Paeciloquinones A, B, C, D, E and F: new potent inhibitors of protein tyrosine kinases produced by Paecilomyces carneus. I. Taxonomy, fermentation, isolation and biological activity.

H. H. Peter, N. Lydon, H. Mett, 1995, The Journal of antibiotics.

Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase.

T. Roberts, H. Piwnica-Worms, N. Lydon, 1992, The Biochemical journal.

The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase.

N. Lydon, I. N. King, M. de Gasparo, 1992, Biochemical and biophysical research communications.

Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src

M. Moran, J. Schlessinger, N. Lydon, 1999, Oncogene.

Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.

N. Lydon, P. Traxler, T. Meyer, 1991, Journal of medicinal chemistry.

Selective Killing of BCR-ABL Positive Cells with a Specific Inhibitor of the ABL Tyrosine Kinase

B. Druker, N. Lydon, E. Buchdunger, 1996 .

[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase.

N. Lydon, P. Traxler, H. Mett, 1995, Journal of medicinal chemistry.

Lessons learned from the development of imatinib.

B. Druker, N. Lydon, 2004, Leukemia research.

Phenylamino‐Pyrimidine (PAP)‐Derivatives: A New Class of Potent and Highly Selective PDGF‐Receptor Autophosphorylation Inhibitors.

N. Lydon, H. Mett, E. Buchdunger, 1996 .

Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411

Pascal Furet, Peter Traxler, Giorgio Caravatti, 1995, J. Comput. Aided Mol. Des..

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

B. Druker, N. Lydon, 2000, The Journal of clinical investigation.

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

J. Melo, N. Lydon, M. Deininger, 1997, Blood.

Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

N. Lydon, H. Mett, E. Buchdunger, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors

Peter Traxler, N. Lydon, H. Mett, 1996 .

Attacking cancer at its foundation

N. Lydon, 2009, Nature Medicine.

Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)

D. Fabbro, T. Meyer, N. Lydon, 1996, Archiv der Pharmazie.

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

Wei Chen, B. Groner, R. Livingston, 1994, Cancer research.

A precision therapy against cancers driven by KIT/PDGFRA mutations

A. Gardino, N. Lydon, M. Heinrich, 2017, Science Translational Medicine.

Potent and Selective Inhibitors of the AbL-Kinase: Phenylaminopyrimidine (PAP) Derivatives.

Jürg Zimmermann, N. Lydon, H. Mett, 1997 .

Src Phosphorylation of the Epidermal Growth Factor Receptor at Novel Sites Mediates Receptor Interaction with Src and P85α (*)

N. Lydon, J. Liebetanz, D. Stover, 1995, The Journal of Biological Chemistry.

Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.

N. Lydon, H. Mett, P. Furet, 1994, Journal of medicinal chemistry.

4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.

N. Lydon, P. Traxler, H. Mett, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Immunochemical mapping of alpha-2 interferon.

N. Lydon, T. L. Nagabhushan, P. Trotta, 1985, Biochemistry.

Expression and partial characterization of rat protein kinase C‐δ and protein kinase C‐ξ in insect cells using recombinant baculovirus

N. Lydon, J. Liebetanz, E. McGlynn, 1992 .

Purification and biochemical characterization of non-myristoylated recombinant pp 6 Oc-src kinase

T. Roberts, H. Piwnica-Worms, N. Lydon, 2005 .

Development of solid-phase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity.

N. Lydon, H. Mett, K. Farley, 1992, Analytical biochemistry.

Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus.

D. Fabbro, T. Meyer, N. Lydon, 1992, Journal of cellular biochemistry.

Modulation of the SH2 Binding Specificity and Kinase Activity of Src by Tyrosine Phosphorylation within Its SH2 Domain (*)

P. Furet, N. Lydon, D. Stover, 1996, The Journal of Biological Chemistry.

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.

N. Lydon, P. Traxler, H. Mett, 1997, Journal de pharmacie de Belgique.

The Structure-Based Design of ATP-Site Directed Protein Kinase Inhibitors

L. Toledo, N. Lydon, D. Elbaum, 1999, Current Medicinal Chemistry.

An E. coli expression system for the rapid purification and characterization of a v-abl tyrosine protein kinase.

N. Lydon, A. Matter, B. Adams, 1990, Oncogene research.

Electroporation of cultured adult rat hepatocytes with the c-myc gene potentiates DNA synthesis in response to epidermal growth factor.

N. Lydon, D. Jans, P. Bentley, 1988, Experimental cell research.

Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase

P. Furet, R. Cozens, N. Lydon, 2001 .

Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).

G. Demetri, N. Lydon, S. George, 2023, Journal of Clinical Oncology.